Acute PE Mortality in the RIETE Registry: Significant Reductions in Mortality Over Time
The RIETE (Registro Informatizado de la Enfermedad TromboEmbólica) registry showed significant temporal changes in the management of patients with pulmonary embolism (PE) (A and B) that were consistent with trial evidence and national and international guidelines. Decreases in length of hospital stay (C) and in the rates of short-term all-cause and PE-specific mortality (D) accompanied these changes in practice. (A) Anticoagulant use (unadjusted p < 0.001 for trend for all comparisons). (B) The use of other pharmacological and interventional therapies (unadjusted p = 0.07 for trend for use of thrombolytics; unadjusted p < 0.01 for trend for use of surgical embolectomy; unadjusted p = 0.90 for trend for use of inferior vena cava filter). (C) Length of stay (unadjusted p < 0.001 for trend). (D) Unadjusted p < 0.01 for trend for 30-day all-cause mortality curve. Unadjusted p < 0.01 for trend for 30-day pulmonary embolism (PE)-related mortality curve. LMWH = low-molecular-weight heparin; UFH = unfractionated heparin.